AU1595001A - Oncolytic combinations for the treatment of cancer - Google Patents
Oncolytic combinations for the treatment of cancerInfo
- Publication number
- AU1595001A AU1595001A AU15950/01A AU1595001A AU1595001A AU 1595001 A AU1595001 A AU 1595001A AU 15950/01 A AU15950/01 A AU 15950/01A AU 1595001 A AU1595001 A AU 1595001A AU 1595001 A AU1595001 A AU 1595001A
- Authority
- AU
- Australia
- Prior art keywords
- cancer
- treatment
- oncolytic
- combinations
- oncolytic combinations
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 230000000174 oncolytic effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16470599P | 1999-11-11 | 1999-11-11 | |
| US60164705 | 1999-11-11 | ||
| PCT/US2000/030892 WO2001034133A2 (en) | 1999-11-11 | 2000-11-09 | Oncolytic combinations for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU1595001A true AU1595001A (en) | 2001-06-06 |
Family
ID=22595715
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU15950/01A Abandoned AU1595001A (en) | 1999-11-11 | 2000-11-09 | Oncolytic combinations for the treatment of cancer |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU1595001A (en) |
| WO (1) | WO2001034133A2 (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU1916601A (en) * | 1999-11-11 | 2001-06-06 | Eli Lilly And Company | Oncolytic combinations for the treatment of cancer |
| IL157443A0 (en) | 2001-03-14 | 2004-03-28 | Bristol Myers Squibb Co | Pharmaceutical compositions for the treatment of cancer including an epothilone analog and a chemotherapeutic agent |
| US20020183277A1 (en) * | 2001-05-15 | 2002-12-05 | Lise Binderup | Combination of vitamin D analogue and pyrimidine nucleoside analogue |
| US20040242676A1 (en) * | 2003-05-30 | 2004-12-02 | Alessi Thomas R. | Method of mitigating the adverse effects of IL-2 |
| GB0410103D0 (en) * | 2004-05-06 | 2004-06-09 | Biolipox Ab | New method |
| TWI461423B (en) * | 2008-07-02 | 2014-11-21 | Astrazeneca Ab | Thiazolidinedione compounds useful in the treatment of pim kinase related conditions and diseases |
| PL388252A1 (en) * | 2009-06-10 | 2010-12-20 | Instytut Farmaceutyczny | Combination therapy of colorectal cancer |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6034256A (en) * | 1997-04-21 | 2000-03-07 | G.D. Searle & Co. | Substituted benzopyran derivatives for the treatment of inflammation |
-
2000
- 2000-11-09 WO PCT/US2000/030892 patent/WO2001034133A2/en not_active Ceased
- 2000-11-09 AU AU15950/01A patent/AU1595001A/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2001034133A3 (en) | 2002-02-14 |
| WO2001034133A2 (en) | 2001-05-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2020501A (en) | Chemotherapy treatment | |
| AU1958897A (en) | Egf-genistein conjugates for the treatment of cancer | |
| AU2495200A (en) | Compositions and methods for the treatment of tumor | |
| AU2003200731A1 (en) | Compositions and methods for the treatment of tumor | |
| AU2003200740A1 (en) | Compositions and methods for the treatment of tumor | |
| AU2003200722A1 (en) | Compositions and methods for the treatment of tumor | |
| AU3791601A (en) | Treatment of coal | |
| EP1176964B8 (en) | Uses of et743 for treating cancer | |
| IL148579A0 (en) | Oncolytic combinations for the treatment of cancer | |
| AU5547000A (en) | Novel treatment | |
| AU2000258650A1 (en) | 2-piperidone compounds for the treatment of cancer | |
| AU6062900A (en) | Substituted indole compounds and their use for the treatment of cancer | |
| AU1916601A (en) | Oncolytic combinations for the treatment of cancer | |
| AU1916501A (en) | Oncolytic combinations for the treatment of cancer | |
| AU7363000A (en) | Method for reducing the risk of cancer | |
| AU1917101A (en) | Oncolytic combinations for the treatment of cancer | |
| AU4556800A (en) | Novel treatment | |
| AU2001257325A1 (en) | Cancer treatment | |
| AU1595001A (en) | Oncolytic combinations for the treatment of cancer | |
| AU1595101A (en) | Oncolytic combinations for the treatment of cancer | |
| AU5552400A (en) | Treatment of cancer | |
| AUPQ367699A0 (en) | Treatment of cancer | |
| AU1592901A (en) | Oncolytic combinations for the treatment of cancer | |
| AU1618901A (en) | Treatment of rosacea | |
| AU2001289127A1 (en) | Tumor treatment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |